Examination of the Effects of Liraglutide on the Mode of Action of Insulin Detemir

Novo Nordisk

Status and phase: Completed; Phase 1

Conditions: Diabetes; Diabetes Mellitus, Type 2

Treatments: Drug: insulin detemir; Drug: liraglutide

Study type: Interventional

Funder types: Industry

Identifiers

NCT00873223

NN2211-3673

Details and patient eligibility

About

This trial is conducted in the United States. The aim of this clinical trial is to investigate whether chronic liraglutide administration affects the mode of action (pharmacokinetics) of insulin detemir

Enrollment: 33 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosed with type 2 diabetes
• BMI less than 45.0 kg/m2
• Insulin naive
• Currently treated with Oral Anti-Diabetic drugs (OADs) and metformin with a HbA1c between 7.0 and 9.5% or currently treated with metformin only with a HbA1c between 7.0 and 10.0%

Exclusion criteria

• Any clinically significant disease other than type 2 diabetes
• Currently using daily insulin
• Thiazolidinione use or other injectable diabetes medications within the last 3 months

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Crossover Assignment

Masking: None (Open label)

---

33 participants in 1 patient group

A

Experimental group

Treatment:

Drug: liraglutide

Drug: insulin detemir